SCHEMBL162564

SCHEMBL162564

CCNC(=O)c1c[nH]nc1[O]

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCNE2 O96020 1/20 0.47
CCNE1 P24864 1/20 0.47
CDK2 P24941 1/20 0.47
LMNA P02545 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
KMT2A Q03164 1/20 0.39
ADRA1D P25100 1/20 0.36
ADRA1A P35348 1/20 0.36
ADRA1B P35368 1/20 0.36
BRD4 O60885 2/20 0.36
CHIA Q9BZP6 1/20 0.35
KDM5A P29375 1/20 0.34
TSHR P16473 2/20 0.33
PIN1 Q13526 1/20 0.33
FUCA1 P04066 1/20 0.33
HPGD P15428 1/20 0.33
HCRTR1 O43613 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL161102 0.86 POLB (0.43) CCNE2CCNE1CDK2L3MBTL1KMT2A
SCHEMBL162023 0.83 TSHR (0.54) CCNE2CCNE1CDK2LMNAL3MBTL1
SCHEMBL1608450 0.82 CCNE2 (0.47) CCNE2CCNE1CDK2LMNAL3MBTL1
SCHEMBL162587 0.81 TP53 (0.44) LMNAKMT2AADRA1DADRA1AADRA1B
SCHEMBL162197 0.79 PLK1 (0.39) ADRA1DADRA1AADRA1BBRD4TSHR
SCHEMBL166279 0.77 MEN1 (0.50) L3MBTL1KMT2AADRA1ATSHRHTT
SCHEMBL163544 0.76 ALDH1A1 (0.41) ADRA1DADRA1AADRA1BHTT
SCHEMBL161439 0.75 POLB (0.40) KMT2AHPGD
SCHEMBL165475 0.73 TSHR (0.43) LMNAKMT2ATSHRHPGD
SCHEMBL161443 0.73 KMT2A (0.50) LMNAL3MBTL1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856210-B2 Pharmaceutical composition for prevention and treatment of amyotrophic lateral sclerosis KYOTO UNIVERSITY (JP) 2018-01-02 US disclosed
EP-2611437-B1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS UNIV KYOTO (JP) 2017-03-29 EP disclosed
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2013-08-29 US disclosed
EP-2611437-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS Kyoto University (JP) 2013-07-10 EP disclosed
WO-2012029994-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS KYOTO UNIVERSITY (JP) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225642-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS SMN1; SMN2, SOD1, SOD3 CCNE2 2820/4885CCNE1 3080/4885CDK2 1418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.